Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Breast 1

Conditions

Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 5Neoplasms 3Glioblastoma 3Colorectal Neoplasms 3Skin Neoplasms 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Hot Flashes 2Vulvodynia 1Thromboembolism 1Severe Acute Respiratory Syndrome 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Hemorrhage 1Pleural Effusion, Malignant 1Platinum Resistant Ovarian Cancer 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Pain, Postoperative 1Neutropenia 1Neoplasm, Residual 1Neoplasm Metastasis 1Myasthenia Gravis 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1

Interventions

Rituximab 155Cyclophosphamide 120fludarabine phosphate 71Whole-Body Irradiation 55Mycophenolic Acid 54Etoposide 53Peripheral Blood Stem Cell Transplantation 46fludarabine 45Melphalan 44Granulocyte Colony-Stimulating Factor 43Busulfan 43Tacrolimus 39Filgrastim 37Vincristine 33Cyclosporine 31Bendamustine Hydrochloride 31Prednisone 29Doxorubicin 29Antilymphocyte Serum 28Methotrexate 27Cytarabine 27Lenalidomide 23Carmustine 22Bortezomib 22plerixafor 20Dexamethasone 19Thiotepa 17Stem Cell Transplantation 17Radiotherapy 17tositumomab I-131 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphoma, Non-Hodgkin × Sodium Chloride × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

NCT01205503 2016-02-24

Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release

University of Kentucky

Phase 2 Completed
32 enrolled 24 charts
BreastLymphoid

Chemotherapy-Related Cognitive Impairment, Breast Neoplasms, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡